Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US

Core Viewpoint - Novartis is launching a direct-to-patient (DTP) platform in the US on November 1, 2025, allowing cash-paying patients to purchase Cosentyx at a 55% discount off the list price, aiming to improve patient access and affordability [1][6]. Group 1: Product and Pricing Strategy - Cosentyx, Novartis' top-selling product in the US, is a biologic approved for treating multiple immune-mediated inflammatory diseases and has been used by over 1.8 million patients globally since its launch in 2015 [1][4]. - The DTP platform will reflect the average savings that insurers and pharmacy benefit managers receive, serving as a proof-of-concept for a direct-selling model for specialty medicines [2][6]. - Novartis plans to expand the DTP option to additional medicines in its portfolio and is exploring a direct-to-business model to sell Cosentyx to large employers [2][6]. Group 2: Patient Assistance Programs - Novartis offers various programs to assist patients in accessing Cosentyx, including options for eligible patients with commercial insurance to pay as little as $0 for their prescriptions [3]. - The Novartis Patient Assistance Foundation provides Cosentyx at no cost for uninsured patients or those with government insurance who meet specific income guidelines [3]. Group 3: Company Overview - Novartis is committed to innovation in medicine development and delivery, aiming to remove barriers in the healthcare system to better serve patients [2][8]. - The company reaches nearly 300 million people worldwide with its medicines, emphasizing its mission to improve and extend lives [8].